JP2019501925A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501925A5
JP2019501925A5 JP2018535388A JP2018535388A JP2019501925A5 JP 2019501925 A5 JP2019501925 A5 JP 2019501925A5 JP 2018535388 A JP2018535388 A JP 2018535388A JP 2018535388 A JP2018535388 A JP 2018535388A JP 2019501925 A5 JP2019501925 A5 JP 2019501925A5
Authority
JP
Japan
Prior art keywords
composition
subject
gdf11 polypeptide
gdf11
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018535388A
Other languages
English (en)
Japanese (ja)
Other versions
JP6948331B2 (ja
JP2019501925A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012505 external-priority patent/WO2017120450A1/en
Publication of JP2019501925A publication Critical patent/JP2019501925A/ja
Publication of JP2019501925A5 publication Critical patent/JP2019501925A5/ja
Priority to JP2021126586A priority Critical patent/JP7288012B2/ja
Application granted granted Critical
Publication of JP6948331B2 publication Critical patent/JP6948331B2/ja
Priority to JP2022193543A priority patent/JP2023014339A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018535388A 2016-01-06 2017-01-06 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する Active JP6948331B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021126586A JP7288012B2 (ja) 2016-01-06 2021-08-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する
JP2022193543A JP2023014339A (ja) 2016-01-06 2022-12-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275645P 2016-01-06 2016-01-06
US62/275,645 2016-01-06
PCT/US2017/012505 WO2017120450A1 (en) 2016-01-06 2017-01-06 Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021126586A Division JP7288012B2 (ja) 2016-01-06 2021-08-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する

Publications (3)

Publication Number Publication Date
JP2019501925A JP2019501925A (ja) 2019-01-24
JP2019501925A5 true JP2019501925A5 (OSRAM) 2020-02-13
JP6948331B2 JP6948331B2 (ja) 2021-10-13

Family

ID=59273941

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018535388A Active JP6948331B2 (ja) 2016-01-06 2017-01-06 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する
JP2021126586A Active JP7288012B2 (ja) 2016-01-06 2021-08-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する
JP2022193543A Pending JP2023014339A (ja) 2016-01-06 2022-12-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021126586A Active JP7288012B2 (ja) 2016-01-06 2021-08-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する
JP2022193543A Pending JP2023014339A (ja) 2016-01-06 2022-12-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する

Country Status (8)

Country Link
US (2) US10980857B2 (OSRAM)
EP (2) EP3399998B1 (OSRAM)
JP (3) JP6948331B2 (OSRAM)
CN (2) CN116059320A (OSRAM)
CA (1) CA3010799A1 (OSRAM)
ES (1) ES2893813T3 (OSRAM)
IL (4) IL293766B2 (OSRAM)
WO (1) WO2017120450A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2924479T3 (es) * 2013-04-08 2022-10-07 Harvard College Composiciones para rejuvenecer las células madre del músculo esquelético
IL293766B2 (en) 2016-01-06 2023-08-01 Harvard College Treatment with gdf11 prevents weight gain, improves glucose loading and reduces hepatosteatosis
CN108619492A (zh) * 2018-05-31 2018-10-09 暨南大学 Gdf11在制备用于治疗肥胖的产品中的应用及治疗肥胖的产品
US10804162B2 (en) 2018-09-27 2020-10-13 Taiwan Semiconductor Manufacturing Co., Ltd. Dual channel gate all around transistor device and fabrication methods thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
EP0698094B1 (en) 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 compositions
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
DK0776337T3 (da) 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
EP0985149A1 (en) 1997-05-30 2000-03-15 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US7795202B2 (en) 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
AU1276399A (en) 1997-11-07 1999-05-31 Genetics Institute Inc. Neuronal uses of bmp-11
US20030170213A1 (en) 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US6555672B1 (en) 1998-07-15 2003-04-29 Metamorphix, Inc. Growth differentiation factor promoter and uses therefor
US7572440B2 (en) 1999-07-30 2009-08-11 Stryker Corporation Method for repairing a defect in an intervertebral disc
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US20030104977A1 (en) 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
EP1790726B1 (en) 2001-02-08 2013-07-03 Wyeth LLC Modified and stabilized GDF propeptides and uses thereof
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20070155661A1 (en) * 2003-02-14 2007-07-05 The Board Of Trustees Of The Leland Standord Junior University Methods and compositions for modulating the development of stem cells
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
JP4695133B2 (ja) 2004-03-23 2011-06-08 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
AU2006239860B2 (en) 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
US20090215671A1 (en) 2005-05-27 2009-08-27 The Regents Of The University Of California Compositions And Methods For Treatment of Neural Disorders Using Transforming Growth Factor-Beta Superfamily Proteins And Their Antagonists
EP3327033A1 (en) 2005-08-19 2018-05-30 Wyeth LLC Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US7972599B2 (en) 2006-03-20 2011-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto
US20080044387A1 (en) 2006-03-24 2008-02-21 The Regents Of The University Of California Artificial niches for enhancement of regenerative capacity of stem cells in aged and pathological environments
AU2007257208B2 (en) 2006-05-17 2013-05-02 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
WO2008021196A2 (en) 2006-08-09 2008-02-21 The Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8404656B2 (en) * 2007-08-09 2013-03-26 Children's Hospital Medical Center Methods of treatment and prevention of diet-induced obesity and sequelae thereof
US8470607B2 (en) 2008-03-20 2013-06-25 Morphotek, Inc. Inhibition of angiogenesis
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8969081B2 (en) 2008-12-10 2015-03-03 The Trustees Of Columbia University In The City Of New York Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid
KR101558642B1 (ko) 2009-02-24 2015-10-12 솔크 인스티튜트 포 바이올로지칼 스터디즈 Tgf-베타 슈퍼패밀리의 설계자 리간드
US20130108645A1 (en) 2010-04-13 2013-05-02 The Johns Hopkins University Methods for enhancing axonal regeneration
US20140127329A1 (en) 2011-03-31 2014-05-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
US8765385B2 (en) * 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
ES2779698T3 (es) 2012-03-19 2020-08-18 Brigham & Womens Hospital Inc Factor 11 de diferenciación del crecimiento (GDF) para el tratamiento de afecciones cardiovasculares relacionadas con la edad
ES2924479T3 (es) 2013-04-08 2022-10-07 Harvard College Composiciones para rejuvenecer las células madre del músculo esquelético
EP3007719B1 (en) 2013-06-11 2021-03-17 President and Fellows of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
EP3008170A4 (en) * 2013-06-11 2016-11-09 Harvard College SC-CELLS AND COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2015034897A1 (en) 2013-09-03 2015-03-12 Mayo Foundation For Medical Education And Research Reducing the risk of major adverse cardiac events
WO2015070076A2 (en) 2013-11-08 2015-05-14 President And Fellows Of Harvard College Methods and compositions for rejuvenating neuromuscular junctions
US10017566B2 (en) 2013-11-12 2018-07-10 The Brigham And Women's Hospital, Inc. Growth differentiation factor (GDF) for treatment of diastolic heart failure
CA2947967A1 (en) 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US20170298128A1 (en) 2014-09-23 2017-10-19 President And Fellows Of Harvard College Methods and compositions for treating age-related disorders
IL293766B2 (en) 2016-01-06 2023-08-01 Harvard College Treatment with gdf11 prevents weight gain, improves glucose loading and reduces hepatosteatosis
EP3523330A1 (en) 2016-10-04 2019-08-14 Fairbanks Pharmaceuticals, Inc. Anti-fstl3 antibodies and uses thereof
WO2019144053A1 (en) 2018-01-19 2019-07-25 President And Fellows Of Harward College Gdf11 variants and uses thereof

Similar Documents

Publication Publication Date Title
Ok et al. Lipid emulsion for treating local anesthetic systemic toxicity
Kondo et al. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease
JP2015187125A5 (OSRAM)
JP2016516073A5 (OSRAM)
JP2019501925A5 (OSRAM)
Becker Sclerostin inhibition for osteoporosis–a new approach
JP2017529382A5 (OSRAM)
JP2018521964A5 (OSRAM)
JP2016514132A5 (OSRAM)
JP2018531938A5 (OSRAM)
JP2016516016A5 (OSRAM)
JP2017533201A5 (OSRAM)
JP2021509916A5 (OSRAM)
JP6889154B2 (ja) グルカゴン類似ペプチド−1受容体亢進剤を含む筋減少症治療用薬学組成物
JP5981141B2 (ja) 多臓器不全症候群(mods)の予防および/または処置のためのインターロイキン−22の使用
JP2018530525A5 (OSRAM)
Toyooka et al. Iatrogenic neuropathies
JP2005529152A5 (OSRAM)
Cetin et al. Paradigm shift in obesity treatment: an extensive review of current pipeline agents
JP2016510738A5 (OSRAM)
US20140162958A1 (en) Copolymer-1 Composition and Methods of Use
WO2018079701A1 (ja) ラクトフェリン活性を有するタンパク質を含む、抗ガン治療補助剤
CA2514816A1 (en) Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia
Ivaskevicius et al. Inhibitor development and management in three non-severe haemophilia A patients with T295A variant
Birjmohun et al. Raising high-density lipoprotein cholesterol for better prevention of cardiovascular disease